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Introduction: Sleep abnormalities, including narcolepsy and cataplexy, are a common feature of Prader-Willi
syndrome. Long-term treatment with the central nervous system stimulant modafinil has not been reported.
In this case report we present a longitudinal perspective of sleep abnormalities in a nine-year-old Caucasian
girl with Prader-Willi syndrome from age two to age nine, and detail the response to treatment with the central
nervous system stimulant modafinil.
Case presentation: Our patient presented at two years of age with hypersomnia and narcoleptic episodes with
cataplectic features. Initial polysomnograph testing revealed adequate sleep efficiency, but increased sleep
fragmentation especially during rapid eye movement sleep. The narcoleptic episodes continued and a repeat
polysomnograph at age five years confirmed features consistent with narcolepsy. Further sleep studies at six
years, including a multiple sleep latency test, demonstrated signs of excessive daytime sleepiness. Treatment
with modafinil was initiated at age seven years six months due to persistent hypersomnia and narcoleptic
symptoms. Two polysomnograph studies were performed following treatment with modafinil, at age eight
years six months and nine years three months. These studies showed excellent sleep efficiency and improvement of
rapid eye movement sleep parameters, supporting the beneficial effects of long-term modafinil therapy.
Conclusions: Long-term modafinil therapy may ameliorate the sleep disturbances of Prader-Willi syndrome and should
be the focus of future clinical trials.
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Prader-Willi syndrome (PWS) is a genetic disorder occur-
ring in 1/10,000 to 25,000 live births. PWS is associated
with infantile hypotonia and failure to thrive, followed by
childhood-onset hyperphagia and progressive obesity,
short stature, hypogonadism, behavioral issues, delayed
cognition and sleep disturbances [1]. Sleep abnormal-
ities are a common symptom of PWS, most often pre-
senting as excessive daytime sleepiness (EDS) [2,3].
Abnormalities in sleep physiology have been reported
including: reduced percentage of rapid eye movement
(REM) sleep and decreased non-rapid eye movement
(NREM) sleep instability, decreased REM sleep latency* Correspondence: haqq@ualberta.ca
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reproduction in any medium, provided the oror sleep-onset REM (SOREM), ventilatory dysfunction, and
obstructive sleep apnea [4]. Additionally, there have been a
number of studies reporting narcoleptic-like symptoms
such as sleep attacks, cataplexy or a transient loss of muscle
tone, sleep paralysis and hypnagogic hallucinations. Modafi-
nil, a central nervous system (CNS) stimulant of postsynap-
tic alpha-1 adrenergic receptors, is currently used in the
treatment of narcolepsy and idiopathic hypersomnia, but
has not been well studied in the treatment of sleep abnor-
malities in PWS [5]. We report a case of a nine-year-old
PWS girl with cataplexy and narcolepsy first noted in
infancy and chronicle the sleep abnormalities over seven
years, and the effect of modafinil on these sleep abnormal-
ities over three years of therapy. This provides a previouslyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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finil on the quality of life of patients with PWS and EDS.
Further, this report also briefly examines the neurobiologic
basis of disordered sleep in PWS.
Case presentation
This nine-year-old Caucasian girl was born at 41 weeks’
gestation via induced vaginal delivery, and weighed
3260g. She was hypotonic and lethargic at birth with
failure to thrive and was nasogastric tube-fed initially
for one month. At 15 months of age, she was diagnosed
with PWS with a rare imprinting center methylation
mutation. She has physical features characteristic of
PWS including almond-shaped eyes, down-turning
corners of the mouth, small hands and a prominent
metopic suture. Other features of PWS include gross
motor delay, social delay, obsessive-compulsive behav-
ior and rigid thinking. Her family history is notable
for a number of members (including our patient’s
father) who suffer from EDS. None of these individ-
uals, however, report characteristics of narcolepsy
such as cataplexy, hypnagogic hallucinations, or sleep
paralysis.
Our patient was referred to a pediatric pulmonologist
at age two years 10 months for a screening polysomno-
graph (PSG) sleep study prior to initiation of growth
hormone (GH) therapy. An initial screening overnight
oximetry study was carried out before the PSG due to
concerns that she might not tolerate the monitoring
equipment. The screening oximetry was normal; no
significant desaturations to suggest obstructive sleep
apnea were found. At the follow-up with the sleep
specialist, our patient’s mother reported episodes sug-
gestive of narcolepsy. Dating back to early infancy, epi-
sodes were reported of our patient falling forward for a
few seconds at a time with her eyes rolling back in her
head. During these events, she was unresponsive, but
appeared to be conscious. The events occurred three
to four times per week and were provoked by laughter.
The episodes typically occurred after waking from a
nap in the mornings, and resolved spontaneously. She
was not sleepy afterwards. The episodes were deter-
mined not to be seizures; no other associated motor
activity, eye deviation or stereotypy consistent with a
description of a seizure was present. Daytime hyper-
somnia was also noted with sleep duration of greater
than 12 hours per night in addition to a two- to three-
hour daytime nap.
The initial sleep study revealed adequate sleep effi-
ciency, but disrupted sleep overall (Table 1). Specific-
ally, our patient did not cycle through all stages of
sleep as expected; sleep fragmentation was noted, especially
during the REM phase. Mild sleep-disordered breathing
(SDB) was identified, consisting of four central apneas, oneobstructive apnea, and three mixed apneas, particularly
within REM sleep. Two obstructive, but no central,
hypopneas were observed. The apnea-hypopnea index
(AHI) was 1.4 events per hour. The average end-tidal
carbon dioxide (EtCO2) measurement was 45mmHg
(maximum of 61mmHg). The average oxygen saturation
(SpO2) was 95 percent (minimum of 78.7 percent).
A repeat overnight PSG was completed at five years
three months of age due to ongoing concerns of EDS
and cataplectic episodes. The goals for treatment were
to optimize school performance and ensure our pa-
tient’s safety. At that time, episodes of cataplexy were
still occurring, mainly in the mornings upon awaken-
ing. The results of the second PSG study (Table 1) were
abnormal and suggestive of narcolepsy. Spikes were noted
on electroencephalography without any seizure activity and
a shortened REM sleep latency was observed. The overall
degree of SDB was improved compared to the previous
measurement. Abnormal respiratory events were limited to
one obstructive apnea and two obstructive hypopneas with
an AHI of 0.4 events per hour. The average EtCO2 was
46mmHg; the SpO2 was also improved with an average of
95 percent (minimum of 87 percent).
Another follow-up PSG was done at age six years and
10 months. This PSG again showed excellent sleep
efficiency and decreased REM sleep latency (Table 1).
However, worsening sleep disruptions were observed,
with increased spontaneous arousals. SDB or obstruct-
ive sleep apnea in REM sleep (an AHI of 4.4 events per
hour) were also worse than previous observations.
Finally, a multiple sleep latency test (MSLT) was per-
formed to objectively quantify the degree of sleepiness
(Table 2). This test consisted of five nap opportunities,
given at two-hour intervals. Her MSLT results showed
the following sleep latencies on five respective naps:
9min 18sec; 1min 44sec; 54sec; 6min 23sec; 3min
55sec. The overall mean sleep latency was 4min 27sec.
Two SOREM periods were also noted.
The results of the above sleep studies combined with
the report of narcoleptic and cataplectic episodes led
to the initiation of treatment at age seven years six
months with a CNS stimulant, modafinil. The initial
dose was 50mg in the mornings and scheduled naps
were presented throughout the day. Two months later,
the dose of modafinil was increased to 100mg daily. With
modafinil treatment, episodes of narcolepsy and cataplexy
were not entirely eliminated, but much improved. A de-
creased level of EDS and fewer cataplectic episodes were
observed post-therapy and safety was no longer a concern.
Our patient had no history of allergy and no adverse effects
of modafinil were reported.
After a year of modafinil therapy a PSG was com-
pleted, at age eight years and six months. This study
demonstrated improvement compared to all previous
Table 1 Polysomnograph results in a patient with Prader-Willi syndrome and narcoleptic and cataplectic symptoms1
2y 10mo 5y 3mo 6y 10mo 8y 5mo 9y 3mo
Sleep architecture
Total sleep time (min) 420.5 489.5 516.5 520 492
Sleep efficiency (%) 84.9 90.8 92.7 94.4 95.1
Sleep stages total sleep time
Stage 1 (%) 6.5 2.2 2.5 0.6 2.1
Stage 2 (%) 43.4 48.1 57.9 64.7 59.3
Stage 3 and 4 (%) 22.5 25.8 18.6 18 18.5
REM (%) 27.6 23.9 21.0 16.8 20.1
Apnea events
Central apnea index (events per hour) 0.57 0 0.46 2.08 2.32
Obstructive apnea index (events per hour) 0.14 0.12 0 0.12 0
Number of mixed events per hour 0.43 0 0.58 0 0
Hypopnea events (events per hour) 0.29 0.25 0.23 0.34 3.05
Apnea-hypopnea index (events per hour) 1.4 0.4 1.3 2.7 5.6
End-tidal carbon dioxide (ETCO2)
Mean total recorded ETCO2 (mmHg) 44.5 46 42 43 45
Maximum total recorded ETCO2 (mmHg) 60.9 60 51 50 54
Oxygen saturation (SaO2)
Mean total recorded SaO2 (%) 94.1 95 97 94 96
Minimum total recorded SaO2 (%) 78.7 87 88 84 84
Anthropometrics
Height (cm) 84 97 104 110 116
Weight (kg) 11.25 15.2 17.4 20.0 21.4
BMI- z score 0.12 0.66 0.39 0.25 −0.23
1Modafinil therapy was initiated at age seven years six months; growth hormone therapy was initiated at age eight years eight months. REM, rapid eye
movement; BMI body mass index.
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However, sleep latency remained short at 6 minutes
and 57 seconds. The REM sleep latency was within
normal limits (1 hour) in contrast to previously abnor-
mal results. Disruption of sleep was also observed, with
increased time spent in stage 2 sleep (67.4 percent ofTable 2 Multiple sleep latency test results in a patient
aged six years 10 months with Prader-Willi syndrome
and narcoleptic and cataplectic symptoms
Nap opportunity Sleep onset latency Sleep onset REM
1 9 minutes, 18 seconds Yes
2 1 minute, 44 seconds No
3 54 seconds No
4 6 minutes, 23 seconds No
5 3 minutes, 54 seconds Yes
Mean sleep latency 4 minutes, 27 seconds
REM, rapid eye movement.total sleep time; TST) and less time in REM sleep (16.8
percent of TST). Additionally, SDB was demonstrated
(mostly central apneas with an AHI of 2.7 events per
hour). These apneas were particularly prominent in
REM sleep; the REM AHI was 10.8 events per hour
and a lower baseline SpO2 of 93 percent and an EtCO2
in the mid-40s was observed. Finally, there was a
slightly elevated periodic limb movement index of 6.6
events per hour.
At age eight years and eight months, our patient was
started on GH and a PSG test was recommended six
months following GH initiation. The dose of modafinil
was increased to 150mg per day to improve the narco-
lepsy and cataplectic episodes. This fifth PSG was done
at age nine years and three months. Again, excellent
sleep efficiency was noted. The REM sleep latency was
slightly prolonged again at 1 hour 21 minutes, and the
proportion of REM sleep was less than expected (20.1
percent of TST). Overall, excellent sleep efficiency was
noted in all stages of sleep despite diminished REM
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SDB was again demonstrated (mostly central apneas
with an AHI of 5.6 events per hour and a REM AHI of
17.6 events per hour). Periodic limb movements again
occurred, with three events per hour. GH therapy elic-
ited several benefits in our patient, including increased
height and growth rate, increased proportional hand and
foot sizes, a decrease in body fat and an increase in lean
body mass and increased physical performance. Other
potential benefits of the GH therapy were not measured,
such as resting energy expenditure, serum cholesterol
and bone mineral density.
Long-term modafinil therapy resulted in objective
improvement in her PSG results, in conjunction with
clinical improvement in her mood and a decreased fre-
quency of naps. An increased level of alertness and
stamina throughout the day was noted by caregivers.
Without modafinil use, our patient became tired and
irritable by early afternoon. With modafinil therapy,
our patient no longer required naps after school and
was more social, alert, and less irritable. A decrease in the
cataplectic episodes was demonstrated; the remaining epi-
sodes were limited to the morning hours prior to modafinil
administration.
Discussion
Sleep abnormalities in patients with PWS lead to detri-
mental effects on daily functioning and learning. Our
report provides a unique longitudinal perspective on
the disordered sleep of a PWS patient, and the effect-
iveness of long-term modafinil use for the treatment of
EDS in a young girl with PWS over the course of three
years. EDS is a common symptom of PWS, affecting
between 70 and 85 percent of PWS individuals [4].
Caregivers often report increased sleepiness in both
children and adults with PWS; individuals with PWS
also self-report higher levels of EDS compared to other
intellectually disabled groups [6]. EDS is also object-
ively demonstrated through abnormal MSLT results in
PWS patients. A collection of studies reviewed by
Maas et al. reported severe sleepiness (MSLT score less
than 5 minutes) in 40 to 50 percent of adults with PWS
and moderate to severe sleepiness (MSLT score less
than 10 minutes) in 70 to 100 percent [2,7]. A combin-
ation of obesity, craniofacial abnormalities, sleep apnea
and abnormalities of sleep structure are proposed con-
tributing factors related to their daytime hypersomnia
[4]. Sleep difficulties can functionally impair attention
and behavior and overall cognitive status and school
functioning [1]. Our patient was initially noted to nap
for two to three hours each day and sleep for 12 hours
during the night. These sleep periods are relatively long
compared to age-matched peers; the average sleep dur-
ation for eight-year-olds is 10.6 ± 0.6h per 24h period[8]. A MSLT performed at age six revealed severe patho-
logical sleepiness, with a MSLT score of less than 5 mi-
nutes. Generally, prepubertal children have mean sleep
latencies greater than 15 minutes [8]. Additionally, the
two SOREMs found on our patient’s MSLT are typical
features of both narcolepsy and PWS [4].
A variety of nighttime sleep architecture distur-
bances are also reported in PWS. The most commonly
observed dysfunction is a decreased REM sleep latency
and the presence of SOREM periods [9]. Other abnor-
malities include reduced percentage of REM sleep,
fragmented REM sleep, and decreased NREM sleep in-
stability [4]. Studies specific to pediatric PWS patients
show a tendency for increased stage I sleep and de-
creased REM latency. The PSG testing over the course
of six years in our patient illustrates many of these findings.
Our patient also had a family history of EDS, which may
contribute to her significant sleep abnormalities.
Modafinil is a psychostimulant prescribed for the
treatment of sleepiness in narcolepsy and other hyper-
somnia disorders. The mechanism or set of mechanisms
through which modafinil promotes arousal and activity
are incompletely understood; however, it is believed to
activate the catecholamine systems at α and β adrenergic
receptors and dopamine receptors [10]. Treatment with
modafinil in small pilot studies has been shown to im-
prove the sleepiness in patients with PWS [11] and was
clinically beneficial for our patient. The drug, however,
has no reported benefit on control of cataplexy [12].
Our patient began treatment with modafinil at age seven
years six months of age (initially at 50mg daily and then
progressed to 150mg daily). Two PSGs were performed
subsequent to the initiation of this drug and both re-
vealed an improvement in a number of sleep parameters.
The PSG performed at ages eight and nine demonstrated
excellent improved sleep efficiencies of 94 and 95 per-
cent, respectively. Additionally, modafinil therapy in
our patient eliminated SOREM periods and decreased
REM sleep latency. However, a reduction in REM
sleep remained at the final PSG at eight years of age,
indicating that not all aspects of sleep abnormality
were ameliorated with modafinil treatment. It is worth
noting that at the increased modafinil dosage (150mg
daily), a longer period of REM sleep was observed.
Therefore, further optimization of modafinil dosing
might be helpful. A MSLT would have been useful in
objectively assessing the impact of modafinil on our
patient’s hypersomnia after a period of therapy; how-
ever, the patient refused further MSLT testing. A
significant improvement in alertness, irritability, and
reduction in naps and cataplectic episodes was noted
by caregivers.
The neurobiologic basis of sleep abnormalities in
PWS are unclear and likely multifactorial. One of the
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obesity and sleep apnea and its disruptive effect on
the quality of sleep. However, resolution of the above
issues in PWS does not completely eliminate their
sleep abnormalities; our subject was not obese [4].
Therefore additional mechanisms for their EDS may
include hypothalamic dysfunction (specifically hypo-
thalamic control of circadian rhythm and NREM/REM
cycling) [10].
Further understanding of how genes in the PWS
locus are connected to sleep functioning offers insight
into an underlying cause of the sleep abnormalities ob-
served in PWS. For example, one of the genes linked to
the phenotype of PWS is MAGEL2 which is expressed
in the suprachiasmatic nucleus (SCN) [13], the loca-
tion of the body’s core circadian clock. These findings
in the mouse model of PWS suggest a possible connec-
tion between the genetics of the PWS, disrupted circa-
dian rhythm and the observed sleep abnormalities. A
disrupted circadian rhythm associated with PWS might
also manifest as specific clinical metabolic (central
obesity, type 2 diabetes, and cardiovascular disease)
and sleep abnormalities observed in this condition.
Research has also illustrated the contribution that al-
tered circadian rhythm and sleep patterns might result
in disrupted metabolic functioning, including impaired
insulin sensitivity and increased risk of diabetes, obes-
ity and cardiovascular events in the general population
(Figure 1) [14]. Therefore, it is important to treat sleep
issues in patients with PWS not only for improvement
of sleep and energy levels, but also to prevent further meta-
bolic deterioration in this disease. While one open-labelFigure 1 Sleep disturbances and metabolic functioning.study of modafinil treatment has been carried out in PWS
patients, duration of treatment was relatively short (1.7 to
14.7 months), no placebo was employed and a small num-
ber of subjects were included (n = 9) [11]. The long-term
benefit of modafinil for EDS and SDB associated with PWS
should be further explored in larger, controlled studies that
also address metabolic outcomes.Conclusions
There are a number of published case reports of
pediatric patients with Prader-Willi syndrome, cata-
plexy and narcolepsy. This report provides novel in-
formation regarding the long-term improvement of
both sleep parameters and narcolepsy/cataplexy post-
modafinil therapy. In our patient, EDS impaired night-
time sleep and narcoleptic/cataplectic episodes resulted
in significant decrease in overall quality of life. Treatment
with modafinil significantly improved these symptoms
and improved the quality of life of our patient over the
course of several years. Given the high incidence of SDB
and sleep disturbances in PWS, it is imperative to rou-
tinely screen for sleep and breathing problems during
clinic visits and work in conjunction with a pediatric
sleep specialist to manage these complex patients.Consent
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